Yeah, so this is another novel biomarker. In this case, we’re measuring in CSF, although it has been also performed previously in plasma. The novelty of the presentation here is that what we did is to measure p-tau205 in an immunoassay instead of a mass spectrometry method. This means that it could be more widely available and done more easily in many different countries in the world compared to the mass spectrometry that needs really devoted machines and also personnel that know how to manage these machines...
Yeah, so this is another novel biomarker. In this case, we’re measuring in CSF, although it has been also performed previously in plasma. The novelty of the presentation here is that what we did is to measure p-tau205 in an immunoassay instead of a mass spectrometry method. This means that it could be more widely available and done more easily in many different countries in the world compared to the mass spectrometry that needs really devoted machines and also personnel that know how to manage these machines. So the thing is that p-tau205 seems to be an intermediate biomarker, meaning that this seems to be later abnormal than p-tau217 that I mentioned before is more related to amyloid and slightly earlier than a late biomarker such as the one that I also mentioned before that is MTBR-tau243. So it suggests that the biomarker p-tau205 seems to become abnormal at the time that tau PET becomes abnormal. So what we try to assess in this presentation is whether we could combine this intermediate or slightly later biomarker with other biomarkers that are more earlier, such as ABETA-42/40 and p-tau217, to really detect different stages of the disease, again, in this idea of using different biomarkers to classify individuals of Alzheimer’s disease. And what we found in this particular study is seeing that really p-tau205 seems to be related to tau pathology as measured by PET, but also it was linked to other downstream effects that happen at late stages of the disease, such as atrophy, cognitive decline, etc. And more interestingly, we had longitudinal data in this individual, so we could clearly see that changes in this biomarker also were related to downstream effects. So kind of showing in a big picture that having different kinds of biomarkers that are related to different stages of the disease, we can classify and stratify participants at different stages of the disease and therefore give them, when available, a more personalized treatment.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
